ID: ALA1938676

Max Phase: Preclinical

Molecular Formula: C11H15N5O4

Molecular Weight: 281.27

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O

Standard InChI:  InChI=1S/C11H15N5O4/c1-2-6-4-16(11(19)13-10(6)18)9-3-7(14-15-12)8(5-17)20-9/h4,7-9,17H,2-3,5H2,1H3,(H,13,18,19)/t7-,8+,9+/m0/s1

Standard InChI Key:  SUUIYCJSXUMURT-DJLDLDEBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 281.27

Molecular Weight (Monoisotopic): 281.1124

AlogP: 0.06

#Rotatable Bonds: 4

Polar Surface Area: 133.08

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.95

CX Basic pKa:

CX LogP: 0.15

CX LogD: 0.03

Aromatic Rings: 1

Heavy Atoms: 20

QED Weighted: 0.46

Np Likeness Score: 0.65

References

1. Herdewijn P, Balzarini J, De Clercq E, Pauwels R, Baba M, Broder S, Vanderhaeghe H..  (1987)  3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.,  30  (8): [PMID:3497272] [10.1021/jm00391a003]

2. Chu CK, Schinazi RF, Ahn MK, Ullas GV, Gu ZP..  (1989)  Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells.,  32  (3): [PMID:2918508] [10.1021/jm00123a018]

3. Srivastav NC, Shakya N, Bhavanam S, Agrawal A, Tse C, Desroches N, Kunimoto DY, Kumar R..  (2012)  Antimycobacterial activities of 5-alkyl (or halo)-3'-substituted pyrimidine nucleoside analogs.,  22  (2): [PMID:22178557] [10.1016/j.bmcl.2011.11.114]

Source

Source(1):

• Scientific Literature